Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study

Table 2 The risk of hospitalization for heart failure of dapagliflozin group compared with DPP-4i group

	Dapagliflozin group			DPP-4i group			cHR	95% CI	aHR	95% CI
	No. of events	Person-year (PY)	Incidence (/1000PY)	No. of events	Person-year (PY)	Incidence (/1000PY)	cHR	95% CI	aHR	95% CI
On treatment analysis
Total	110	28,478	3.86	2210	325,344	6.79	0.56	0.46–0.68	0.58	0.46–0.74
CVD	64	5605	11.42	1196	57,819	20.69	0.54	0.42–0.69	0.55	0.41–0.74
Non-CVD	46	22,873	2.01	1014	267,525	3.79	0.53	0.39-.071	0.66	0.46–0.95
Intention-to-treat analysis
Total	267	54,145	4.93	4270	546,982	7.81	0.63	0.56–0.71	0.70	0.60–0.82
CVD	148	10,657	13.89	2084	93,600	22.26	0.62	0.53–0.74	0.66	0.53–0.81
Non-CVD	119	43,488	2.74	2186	453,382	4.82	0.57	0.47–0.68	0.74	0.58–0.94

DPP-4i Dipeptidyl-peptidase 4 inhibitor, PY person-year, cHR crude hazard ratio, aHR adjusted hazard ratio, CI confidence interval, CVD Patients with underlying cardiovascular disease, Non-CVD patients without underlying cardiovascular disease

ISSN: 1475-2840